MiR-210 Up-Regulation Inhibits Proliferation and Induces Apoptosis in Glioma Cells by Targeting SIN3A

AEG 1 Chao Shang
B 2 Yang Hong
C 3 Yan Guo
CD 2 Yun-hui Liu
AE 1 Yi-xue Xue

Background: The aim of this study was to determine whether miR-210 can affect the apoptosis and proliferation of human U251 glioma cells from down-regulating SIN3A.

Material/Methods: The expression of miRNA-210 was detected by quantitative real-time PCR in normal brain tissue and glioma samples. The apoptosis and proliferation ability of U251 cells were analyzed by MTT and flow cytometry assay after anti-miR-210 transfection. For the regulation mechanism analysis of miR-210, TargetScan, PicTar, and microRNA were selected to predict some potential target genes of miR-210. The predicted gene was identified to be the direct and specific target gene of miR-210 by luciferase activities assay and Western blot. RNA interference technology was used to confirm that the apoptosis and proliferation effects of miR-210 were directly induced by SIN3A.

Results: The expression of miR-210 increased significantly in glioma in comparison with normal brain tissue. The silence of miR-210 expression could inhibit the proliferation of U251 cells and induce the apoptosis. Mechanism analysis revealed that SIN3A was a specific and direct target gene of miR-210. The siRNA-SIN3A could down-regulate the expression of SIN3A protein, which was up-regulated in U251 cells by anti-miR-210 transfection, and our experiments found that silence of SIN3A could inhibit the apoptosis and sharply increase the proliferation of U251 cells. The regulation effects of anti-miR-210 on apoptosis and proliferation can be reversed respectively by the expression silence of SIN3A.

Conclusions: Aberrantly expressed miR-210 regulates human U251 glioma cells apoptosis and proliferation partly through directly down-regulating SIN3A protein expression. This might offer a new potential therapeutic stratagem for glioma.

MeSH Keywords: Glioma • MicroRNAs • Neoplastic Stem Cells

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/892994
Background

Glioma is the most general primary tumor in nervous system, and has the highest mortality and mortality among endocrinal tumors, because of the marked characteristics of malignant proliferation and invasion [1,2]. Gliomas are rarely curable. Treatment for a glioblastoma is customized to the individual patient and may include surgery, radiation therapy, chemotherapy, or observation. So far, surgery is the most important initial approach. Chemotherapy and radiotherapy after initial surgical resection is regarded as an effective treatment plan to prevent recurrence and metastasis [3]. However, chemotherapy does not work for everyone with a glioma and it only helps about half the people treated. For this reason, the prognosis for patients, especially with high-grade glioma, is still gloomy, despite being given prompt and comprehensive treatment. The median survival time for adults with an anaplastic astrocytoma is about 2–3 years, and for those with more aggressive glioblastomas, median survival drops off to about 12~14.6 months, with a 2-year median survival rate of 30% [4].

MicroRNAs (miRNAs) are small endogenous RNAs that are non-coding. MiRNAs display abnormal expression and functions in various kinds of malignancies, which act as different kinds of tumor-related genes [5,6]. MiR-210 is an oncogene that is high-expressed in some kinds of malignant tumors, including glioblastomas. MiR-210 can specifically inhibit many target genes helpful to apoptosis and/or inhibitive to proliferation [7,8]. Evidence suggests that miR-210 is an anti-apoptotic factor and functions at least in part by targeting a host of pro-apoptotic genes [9,10]. MiR-210 could silence the expression of some genes helpful to apoptosis and inhibit apoptosis in cancer cells.

Our previous microarray assays found miR-210 had higher expression in glioma samples than in controls, suggesting that miR-210 might be an oncogene in tumorigenesis of glioma. In this study, we investigated how the molecular mechanism of miR-210 regulates glioma cells apoptosis and proliferation. Further related research might help the development of new therapeutic stratagems against glioblastoma.

Material and Methods

Clinical specimens

The study was approved by the Ethics Committees of Chian Medical University, and we obtained patient permission before surgery. A total of 46 glioma and corresponding paracancerous tissues were obtained through surgery. The patients had not experienced radiation or chemotherapy before surgery. The patient group included 31 men and 15 women (mean age: 53.9±3.7 years, age range: 47–68 years); and included 20 cases of astrogliomas (Grade I–II), 15 cases of anaplastic gliomas (Grade III), and 11 cases of glioblastomas (GBM, Grade IV). After surgery, the tissue samples were stored at -80°C, and the pathological information was obtained soon after.

Quantitative real time-PCR (qRT-PCR)

After total RNA was extracted from tissue and cell samples, cDNA was synthesized and used to detect the mRNA expression with an miRNA detection kit (Invitrogen, USA) [11]. The samples were normalized to 18s and the 18sCT-30 were calculated with 2-ΔΔCT using the Applied Biosystems 7500.

Transfection

Twenty-four hours before transfection, an appropriate concentration (about 80%) of resuspended U251 cells were seeded on 6-well plates. The miRNAs (Life Technologies, USA) were transfected into U251 cells with Lipofectamine™ 2000 reagent (Invitrogen, USA), and the final concentration of miRNAs was 60 nM. The transfected cells were incubated for 4 h, and normal media was added. After 48 h, the cells were harvested for further detection.

Cell proliferation assay

Cells were seeded in 96-well plate with 2×10^4 cells per well. Twenty μl of 0.5 mg/ml MTT solution (Sigma, USA) was added to each well, and the 96-well plate was incubated at 37°C. We cleaned up the media after 4 h, and added 0.2 ml DMSO to each well. The 96-well plate was incubated 30 min, and read on an enzyme-labeled instrument (Bio-Rad, USA) with 570-nm wavelength. The obtained numerical values were used to construct the cell viability. The cell viability=(OD value of test group – OD value of blank group)/(OD value of control group – OD value of blank group).

Flow cytometry detection

Cells (5×10^4) were harvested and the Annexin V-FITC apoptosis detection kit (Biosea, China) was used to examine the apoptosis rate in accordance with the manufacturer’s instruction. The cells were mixed with 10 μl Annexin and incubated at room temperature away from light for 15 min, and then 5 μl propidium iodide (PI, 10 mg/L) was added to each. Then the cells were read by flow cytometry (BD, USA) (Ex 488 nm, Em 635 nm) and the obtained numerical values were analyzed with CELLQuest 3.0 software (BD, USA). Annexin V-positive cells were regarded as apoptosis cells. The cells were counted by a dual-color flow cytometric method.

Target prediction

The prediction of the SIN3A 3’-UTR as a miRNA binding target was determined using TargetScan (www.targetscan.org),
Small RNA interference

The specific small interfering RNAs (siRNA) to SIN3A gene and matching negative control oligonucleotides were synthesized by Invitrogen and transfected into U251 cells. At 48 h post-transfection, the SIN3A protein was detected to identify the silencing efficiency.

Statistical analysis

All experiments were repeated 3 times. All numerical data are presented as mean ± standard deviation (SD) and analyzed using with SPSS 13.0 software (SPSS, USA). One-way analysis of variance was used to analyze statistical significance. When P value was lower than 0.05, there was statistical significance, marked by (*). If P value was lower than 0.001, the statistical significance existed, indicated by (**).

Results

MiR-210 up-regulated in glioma specimens

To research the potential effect of miR-210 in glioma, the expression of miR-210 was first detected in 46 glioma and corresponding paracancerous tissues samples. In contrast to matching paracancerous tissues, the miR-210 expression in glioma increased remarkably (p<0.001) (Figure 1). The miR-210 expression in glioma U251 cells was similar to that in glioma tissue, and much higher than that in paracancerous tissues. Further, the expression of miR-210 was positively correlated with the pathologic grades (r=0.197, P=0.016, Pearson’s correlation coefficient; i.e., negatively correlated with the differentiation) of glioma (P<0.05) (Table 1).

MiR-210 functions as an oncogene in glioma cells

We investigated whether miR-210 influences the apoptosis and proliferation using U251 cells. The anti-miR-210 was transfected into U251 cells to inhibit the miR-210 expression. In comparison to control U251 cells, the proliferation ability of U251 cells transfected with anti-miR-210 was markedly reduced by MTT assay (Figure 2A). The flow cytometry showed that the apoptosis rate of U251 cells transfected with anti-miR-210 was 6.41% and that of control U251 cells was 3.27%; the statistical analysis revealed that the apoptosis rate increased significantly (Figure 2B). The expression of cleaved caspase3 showed a significant increasing after anti-miR-210 transfection (Figure 2C, 2D).

SIN3A was a direct and specific target of miR-210 in U251 cells

We then investigated the mechanisms by which miR-210 affects the apoptosis and proliferation phenotype in U251 cells.
Online search to the target genes of miR-210 by PicTar, microRNA, and TargetScan indicated that SIN3A gene was a possible target of miR-210 (Figure 3A).

qRT-PCR was used to detect that the expression of SIN3A gene down-regulated significantly in glioma tissues, in contrast with matching paracancerous tissues (Figure 1).

**Table 1.** Correlation between miR-210 expression in brain glioma tissue and pathological differentiation.

| Differentiation (Grade) | Number of cases | miR-210 expression relative quantification (gliomas/peri-cancerous tissues) | P value |
|-------------------------|-----------------|--------------------------------------------------------------------------|---------|
| Medium-well differentiated (Grade I-II) | 20 | 1.425±0.152 | |
| Anaplastic glioma (Grade: III) | 15 | 1.529±0.157 | <0.05 |
| Glioblastoma (Grade: IV) | 11 | 1.739±0.161 | |

* A one-way ANOVA showed that miR-210 expression in brain glioma tissue was statistically different among the three groups with different pathological differentiation of glioma (P<0.05). LSD test showed significant difference between groups of medium-well differentiated glioma (Grade I-II) and anaplastic glioma (Grade: III) (P=0.03), as well as groups of medium-well differentiated glioma (Grade I-II) and Glioblastoma (GBM, Grade: IV) (P=0.01).

**Figure 2.** (A) Impact of SIN3A gene expression changes on the proliferation ability of U251 cells. (B) Impact of SIN3A gene expression changes the apoptosis rate of U251 cells. (C) Western blot analysis for SIN3A and cleaved Caspase3 expression of U251 cells treated with anti-miR-210 and siRNA-SIN3A transfection. GAPDH was used as a reference control. (D) Quantitative analysis of the relative protein levels of SIN3A and cleaved Caspase3 normalized to those of GAPDH was shown. *, ** P <0.05 vs. control U251 cells; #, ## P <0.05 vs. U251 cells with anti-miR-210. IDV is the abbreviation for “integrated density values”, which is calculated by computerized image analysis system (Fluor Chen 2.0) and normalized with that of GAPDH.
analysis showed a negative relationship between the expression of miR-210 and SIN3A.

The luciferase reporter assay was set-up to identify the direct miR210-SIN3A interaction. The pre-miR-210 and different reporter vectors were cotransfected into U251 cells. As shown in Figure 3B, the relative luciferase activity was much lower in U251 cells cotransfected with WT vector and pre-miR-210 than in other transfected U251 cells. This indicated that miR-210 could specifically bind to seed zone of SIN3A 3’UTR to inhibit its expression, but Mut vector could not combine with miR-210 to decrease the relative luciferase activity. SIN3A is a specific and direct target gene of miR-210.

To make sure the regulative effects of miR-210 to endogenous SIN3A expression, results certified that pre-miR-210 could increase miR-210 expression level efficiently, and anti-miR-210 showed a contradictory regulative effect. The Western blot result showed that compared with control, the SIN3A protein level was significant suppressed with miR-210 enhancement and was up-regulated significantly in U251 cells transfected with anti-miR-210 (Figure 3C, 3D), whereas the qRT-PCR result showed that endogenous SIN3A expression was not significant alteration in U251 cells (data not shown). The conclusion can be made that miR-210 negatively regulate endogenous SIN3A expression at the post-translational level.

**SIN3A expression mediates the effect of miR-210 on U251 cells apoptosis and proliferation**

Because miR-210 could regulate the apoptosis and proliferation of U251 cells, and SIN3A was the target gene of miR-210, we studied the physiological role of miR-210-target SIN3A in U251 cells after RNA interference SIN3A. As shown in Figure 2C and 2D, combined with siRNA-control, after siRNA-SIN3A treatment, protein expression of SIN3A was significantly reduced in U251 cells transfected with anti-miR-210. After the expression of SIN3A protein was inhibited, combined with the U251 cells transfected with anti-miR-210, the proliferation ability was markedly increased (Figure 2A), and the apoptosis ratio of U251 cells decreased from 6.41% to 2.52%, which was statistically significant (Figure 2B).

Combined with our substantial evidence that miR-210 inversely regulated SIN3A expression, we believe that miR-210-controlled
apoptosis and proliferation of U251 cells is mediated to a large extent through SIN3A down-regulation.

Discussion

Glioma cells have vigorous proliferation ability and low apoptosis rate, and have powerful resistance to radiation, chemotherapy, and biological treatment [13–15]. Those characteristics contribute to malignant growth of tumors and might be a vital reason for the inevitable recurrence of glioma [16].

Aberrant miRNA expression can regulate critical biological behaviors, such as apoptosis and proliferation, which may promote glioma cells development and lead to poor prognosis [17,18]. Our research discovered miR-210 was also over-expressed in brain glioma. Knockdown of miR-210 could increase the apoptosis rate of U251 cells and suppress the proliferation. Thus, we showed that miR-210 is very important in the genesis and development of glioma.

Because miRNA acts by targeting various genes, such as miR-22 and CBP, miR-21 and FASLG, miR-10b and E-cadherin [19–21], we speculate that miR-210 regulated some single genes to modify the regulation network and trigger cell apoptosis and proliferation in U251 cells in our study. Computational algorithms are effective tools to predict and validate the miRNA gene targets. Through analysis using TargetScan, PicTar, and microRNA, a number of important candidate targets for miR-210 were predicted. Among these potential targets, SIN3A is the most intriguing target. The SIN3A gene is a member of the SIN3 transcription regulator family and acts as a transcriptional repressor. SIN3A have been regarded as very important effectors of cell biological characteristics, such as cell cycle and apoptosis and invasion [22–24]. SIN3A gene is thought to modify gene expression through its role as histone deacetylases (HDACs). SIN3A could interact with MXI1 to repress MYC responsive genes and antagonize MYC oncogenic activities [25,26]. Few previous studies have demonstrated the abnormal expression and function of SIN3A in tumors, and there is not a conclusive report about SIN3A in glioma.

References:

1. Kuhnt D, Becker A, Ganslandt O et al: Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol, 2011; 13(12): 1339–48
2. Houdek Z, Cendelín J, Kulda V et al: Intracerebellar application of P19-
3. Mrugala MM: Advances and challenges in the treatment of glioblastoma: a clinician’s perspective. Discov Med, 2013; 15(83): 221–30
4. Nieder C, Astner ST, Mehta MP et al: Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol, 2008; 31: 300–5
5. Shang C, Lu YM, Meng LR: MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Med Sci Monit, 2012; 18(4): BR149–55
6. Zhang H, Guo Y, Shang C et al: miR-21 downregulated TCF21 to inhibit KiSS1 in renal cancer. Urology, 2012; 80(6): 1298–302
7. Wang F, Xiong L, Huang X et al: miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res, 2013; 11(1): 657–67
8. He J, Wu J, Xu N et al: MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res, 2013; 41(1): 498–508

Conclusions

In summary, aberrantly expressed miR-210 regulates human U251 glioma cells apoptosis and proliferation, partly through directly down-regulating SIN3A protein expression; this might offer a new potential therapeutic stratagem for glioma. Nevertheless, further research is essential to identify the detailed molecular mechanism of miR-210 in the genesis and development of glioma.

Competing interests

All authors announce that they have no competing interests.
9. Wang Z, Yin B, Wang B et al: MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3. Oncol Res, 2014; 21(3): 145–54

10. Chio CC, Lin JW, Cheng HA et al: MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch Toxicol, 2013; 87(3): 459–68

11. Shang C, Zhang H, Guo Y et al: MiR-320a down-regulation mediates bladder carcinoma invasion by targeting TGB3. Mol Biol Rep, 2014; 41(4): 2521–27

12. Kumar M, Singh M, Singh SB: Optimization of conditions for expression of recombinant interferon-g in E. coli. Mol Biol Rep, 2014; 41(10): 6537–43

13. Dahlrot RH: The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dan Med J, 2014; 61(10): B4944

14. Lim YC, Roberts TL, Day BW et al: Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells. Mol Oncol, 2014; 8(8):1603–15

15. Fukai J, Koizumi F, Nakao N: Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase. PLoS One, 2014; 9(6): e104538

16. Wang F, Zamora G, Sun CH et al: Increased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced non-viral transfection of the cytosine deaminase suicide gene. J Neurooncol, 2014; 118(1): 29–37

17. Chen T, Wang XY, Li C, Xu SJ: Downregulation of microRNA-124 predicts poor prognosis in glioma patients. Neurol Sci, 2014 [Epub ahead of print]

18. Wang L, Shi ZM, Jiang CF et al: MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget, 2014; 5(14): 5416–27

19. Yang J, Chen L, Yang J et al: MicroRNA-22 targeting CBP protects against myocardial ischemia-reperfusion injury through anti-apoptosis in rats. Mol Biol Rep, 2014; 41(1): 555–61

20. Shang C, Guo Y, Hong Y et al: MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG. Mol Biol Rep, 2014 [Epub ahead of print]

21. Liu Y, Zhao J, Zhang PY et al: MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med Sci Monit, 2012; 18(8): BR299–308

22. Ji Q, Hu H, Yang F et al: CRL4B interacts and coordinates with SIN3A/HDAC complex to repress CDKN1A in driving cell cycle progression. J Cell Sci, 2014; 127(21): 4679–91

23. Farhana L, Dawson MI, Dannenberg JH et al: SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor-kappaB activation, c-Fos/c-Jun expression, and cellular apoptosis. Mol Cancer Ther, 2009; 8(6): 1625–35

24. Das TK, Sangodkar J, Negre N et al: Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene, 2013; 32(26): 3184–97

25. Rao G, Alland L, Guida P et al: Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of theMyc antagonist Mxi1. Oncogene, 1996; 12(5): 1165–72

26. Garcia-Sanz P, Quintanilla A, Lafita MC et al: Sin3b interacts with Myc and decreases Myc levels. J Biol Chem, 2014; 289(32): 22221–36